Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study

PURPOSE: Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on corrected QT interval using Fridericia’s formula (QTcF). METHODS: Eligible patients with advanced solid tumors received...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Chemother Pharmacol
Päätekijät: Munasinghe, Wijith, Stodtmann, Sven, Tolcher, Anthony, Calvo, Emiliano, Gordon, Michael, Jalving, Mathilde, de Vos-Geelen, Judith, Medina, Diane, Bergau, Dennis, Nuthalapati, Silpa, Hoffman, David, Shepherd, Stacie, Xiong, Hao
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2016
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5083757/
https://ncbi.nlm.nih.gov/pubmed/27709282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3156-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia